AI news story
Using AI to Develop New Drugs
Shawn Rosemarin, Global VP of Research & Development, Customer Engineering, Everpure and Pradeep Bandaru, Head of Platforms & AI Workflows at Sanofi join Carol Massar and Tim Stenovec to discuss the way better data can help the pharmaceutical industr
Editor's take
Sanofi executives detailed how improved data accessibility and quality are accelerating their AI-driven drug discovery efforts. This isn't about novel AI architectures but rather the foundational work of organizing and cleaning vast biological and chemical datasets, enabling faster hypothesis generation and validation for new therapeutic candidates.
The significance lies in streamlining the notoriously slow and expensive pharmaceutical R&D pipeline, potentially bringing life-saving treatments to market sooner. Pharmaceutical giants like Pfizer and Novartis are also investing heavily in AI for drug discovery, making Sanofi's focus on data infrastructure a critical differentiator in this competitive space.
Future developments to monitor include the specific types of AI models Sanofi is deploying on this improved data, and whether their approach yields a measurable reduction in clinical trial timelines and costs compared to industry averages. The success of this data-centric strategy will also inform how other major pharmaceutical players prioritize their AI investments.
Signal score: 5
This event was corroborated by 8 independent sources. The signal score weighs cross-source corroboration, recency, source weight and topic salience. How we rank stories.
Original reporting
This story summarises reporting published by Bloomberg. Read the original article at Bloomberg.